These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 17667938)

  • 1. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma.
    Scavelli C; Nico B; Cirulli T; Ria R; Di Pietro G; Mangieri D; Bacigalupo A; Mangialardi G; Coluccia AM; Caravita T; Molica S; Ribatti D; Dammacco F; Vacca A
    Oncogene; 2008 Jan; 27(5):663-74. PubMed ID: 17667938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
    Vacca A; Scavelli C; Montefusco V; Di Pietro G; Neri A; Mattioli M; Bicciato S; Nico B; Ribatti D; Dammacco F; Corradini P
    J Clin Oncol; 2005 Aug; 23(23):5334-46. PubMed ID: 15939924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
    Moschetta M; Di Pietro G; Ria R; Gnoni A; Mangialardi G; Guarini A; Ditonno P; Musto P; D'Auria F; Ricciardi MR; Dammacco F; Ribatti D; Vacca A
    Eur J Cancer; 2010 Jan; 46(2):420-9. PubMed ID: 19914061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
    Vacca A; Ribatti D; Presta M; Minischetti M; Iurlaro M; Ria R; Albini A; Bussolino F; Dammacco F
    Blood; 1999 May; 93(9):3064-73. PubMed ID: 10216103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial differentiation of hematopoietic stem and progenitor cells from patients with multiple myeloma.
    Ria R; Piccoli C; Cirulli T; Falzetti F; Mangialardi G; Guidolin D; Tabilio A; Di Renzo N; Guarini A; Ribatti D; Dammacco F; Vacca A
    Clin Cancer Res; 2008 Mar; 14(6):1678-85. PubMed ID: 18347168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
    Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
    Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The significance of IGF-1, VEGF, IL-6 in multiple myeloma progression].
    Guo YQ; Chen SL
    Zhonghua Xue Ye Xue Za Zhi; 2006 Apr; 27(4):231-4. PubMed ID: 16875552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.
    Ribatti D; Vacca A; Nico B; Quondamatteo F; Ria R; Minischetti M; Marzullo A; Herken R; Roncali L; Dammacco F
    Br J Cancer; 1999 Feb; 79(3-4):451-5. PubMed ID: 10027312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma.
    Rendtlew Danielsen JM; Knudsen LM; Dahl IM; Lodahl M; Rasmussen T
    Br J Haematol; 2007 Sep; 138(6):756-60. PubMed ID: 17760807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets.
    Berardi S; Caivano A; Ria R; Nico B; Savino R; Terracciano R; De Tullio G; Ferrucci A; De Luisi A; Moschetta M; Mangialardi G; Catacchio I; Basile A; Guarini A; Zito A; Ditonno P; Musto P; Dammacco F; Ribatti D; Vacca A
    Oncogene; 2012 May; 31(18):2258-69. PubMed ID: 21963844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
    Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
    Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
    Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Kimlinger TK; Greipp PR; Rajkumar SV
    Blood; 2004 Aug; 104(4):1159-65. PubMed ID: 15130943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paraproteinaemias: pathophysiology.
    Samson D
    Schweiz Med Wochenschr; 2000 Nov; 130(44):1643-8. PubMed ID: 11103434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis in multiple myeloma.
    Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
    Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma.
    Kimlinger T; Kline M; Kumar S; Lust J; Witzig T; Rajkumar SV
    Haematologica; 2006 Aug; 91(8):1033-40. PubMed ID: 16870555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Rajkumar SV; Lacy MQ; Kyle RA
    Blood Rev; 2007 Sep; 21(5):255-65. PubMed ID: 17367905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
    De Luisi A; Ferrucci A; Coluccia AM; Ria R; Moschetta M; de Luca E; Pieroni L; Maffia M; Urbani A; Di Pietro G; Guarini A; Ranieri G; Ditonno P; Berardi S; Caivano A; Basile A; Cascavilla N; Capalbo S; Quarta G; Dammacco F; Ribatti D; Vacca A
    Clin Cancer Res; 2011 Apr; 17(7):1935-46. PubMed ID: 21307145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.
    De Luisi A; Binetti L; Ria R; Ruggieri S; Berardi S; Catacchio I; Racanelli V; Pavone V; Rossini B; Vacca A; Ribatti D
    Angiogenesis; 2013 Oct; 16(4):963-73. PubMed ID: 23881169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.